Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
Rhea-AI Summary
Citius Pharmaceuticals (Nasdaq: CTXR) closed a registered direct offering priced at-the-market, selling 5,076,143 shares (or pre-funded warrants) at $0.985 per share and issuing unregistered warrants to purchase up to 5,076,143 shares at a $0.86 exercise price.
The aggregate gross proceeds were approximately $5.0 million before placement agent fees and expenses. The company intends to use net proceeds to support the commercial launch of LYMPHIR™, product development and general corporate purposes. H.C. Wainwright acted as exclusive placement agent.
AI-generated analysis. Not financial advice.
Positive
- Aggregate gross proceeds of approximately $5.0 million
- Proceeds intended to support LYMPHIR commercial launch and development
- Registered direct offering executed under an effective shelf registration
Negative
- Issuance of 5,076,143 shares (or pre-funded warrants) may dilute shareholders
- Unregistered warrants exercisable at $0.86 could increase dilution upon exercise
News Market Reaction – CTXR
On the day this news was published, CTXR declined 10.26%, reflecting a significant negative market reaction. Argus tracked a trough of -16.6% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $20.88M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CTXR was up 8.5% pre-announcement with high volume, while momentum peers showed mixed moves (1 up, 2 down; median about -4%), suggesting company-specific dynamics within a broadly active biotech group.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 21 | Registered direct closing | Negative | -6.5% | Closed $6M at-the-market registered direct with common stock and warrants. |
| Oct 21 | Registered direct pricing | Negative | -7.2% | Announced $6M registered direct with shares and common warrants for LYMPHIR funding. |
| Jul 17 | Public offering closing | Negative | -4.1% | Closed $9M public offering of shares and warrants at $1.32 per share. |
| Jul 16 | Public offering pricing | Negative | -8.6% | Priced $9M public offering with 6.82M shares and matching-price warrants. |
| Jun 12 | Registered direct closing | Negative | -8.9% | Closed $6M direct plus extra warrants, proceeds for LYMPHIR and corporate uses. |
Financing and offering announcements have typically been followed by single-digit percentage declines, with an average move of about -7.06% over five past events.
Over the past year, Citius has repeatedly used equity and warrant offerings to fund LYMPHIR™ commercialization and general corporate needs. Five tagged offering events between June 12, 2025 and October 21, 2025 each involved multi-million‑dollar raises with common stock plus warrants, and all saw modest next‑day price declines, averaging -7.06%. Today’s registered direct and concurrent private placement continue this pattern of raising capital tied to LYMPHIR launch and development funding.
Historical Comparison
In the past year, CTXR reported 5 equity or warrant offerings, with an average next‑day move of -7.06%. Similar capital raises have historically coincided with modest share price pressure.
Financings have steadily funded LYMPHIR™ commercialization, pairing common stock with warrants across multiple offerings to support launch and development activities.
Market Pulse Summary
The stock dropped -10.3% in the session following this news. A negative reaction to this offering would be consistent with the company’s track record, where five prior equity or warrant financings produced an average -7.06% next‑day move. The transaction adds new shares and long‑dated warrants while raising only $5M, against a backdrop of going‑concern language and ongoing cash needs. Selling pressure could reflect dilution concerns and existing warrant overhang rather than any change in LYMPHIR™ fundamentals.
Key Terms
registered direct offering financial
pre-funded warrants financial
warrants financial
exercise price financial
shelf registration statement regulatory
Regulation D regulatory
AI-generated analysis. Not financial advice.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
The aggregate gross proceeds to the Company from the offering were approximately
The common stock (or pre-funded warrants) (but not the unregistered warrants and the shares of common stock underlying the unregistered warrants) described above were offered pursuant to a "shelf" registration statement (File No. 333-277319) filed with the Securities and Exchange Commission ("SEC") on February 23, 2024 and declared effective on March 1, 2024. The registered direct offering was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to the registered direct offering was filed with the SEC and is available at the SEC's website at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the registered direct offering may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor,
The unregistered warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying such unregistered warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the unregistered warrants and underlying shares of common stock may not be offered or sold in
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately
Forward Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price, and includes all statements related to the intended use of net proceeds from the offering. Factors that could cause actual results to differ materially from those currently anticipated are: our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; our ability to maintain Nasdaq's continued listing standards; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; risks relating to the results of research and development activities, including those from any new pipeline assets; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our SEC filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025, as amended January 28, 2026, as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Investor Contact
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
Media Contact
STiR-communications
Greg Salsburg
Greg@STiR-communications.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-closing-of-registered-direct-offering-of-5-million-priced-at-the-market-under-nasdaq-rules-302753106.html
SOURCE Citius Pharmaceuticals, Inc.